The Use of Tofacitinib Has a Potential Effect on Improving the Outcomes of Melanoma Differentiation-Associated Gene 5-Related Interstitial Lung Disease.
Zhichun LiuNing ZhuoJie LiZhenhua WenPublished in: The Journal of rheumatology (2022)
We read with great interest the recent retrospective analysis by Fan and colleagues on the outcomes of tofacitinib (TOF) or tacrolimus (TAC) in combination with glucocorticoids for melanoma differentiation-associated gene 5 (MDA5)-related interstitial lung disease (MDA5-ILD), published in The Journal of Rheumatology 1 The authors mainly investigated whether TOF exposure was associated with reduced mortality at 6 months and 1 year, and also compared the incidence of adverse events and discontinuation rates in the TOF and TAC groups for the treatment of MDA5-ILD.
Keyphrases
- interstitial lung disease
- rheumatoid arthritis
- systemic sclerosis
- mass spectrometry
- ms ms
- breast cancer cells
- idiopathic pulmonary fibrosis
- risk factors
- disease activity
- genome wide
- copy number
- cell cycle arrest
- ulcerative colitis
- genome wide identification
- cardiovascular events
- skin cancer
- gene expression
- systematic review
- cell death
- atomic force microscopy
- dna methylation
- juvenile idiopathic arthritis
- systemic lupus erythematosus
- combination therapy
- human health